Clinical Study for the Efficacy and Safety of Anlotinib Combined with Docetaxel in the Second Line and above Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023186

Enrollment

Unknown

Registered

2019-05-15

Start date

2019-05-20

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

single arm:combination of amlotinib and docetaxel

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years, with good compliance. 2. Histological/cytological diagnosis as non-squamous non-small cell lung cancer. 3. At least one target lesion has not been treated by radiotherapy with RECIST 1.1 definition and measurable lesion in the past three months. 4. Patients who have failed or cannot tolerate greater than or equal to one treatment,including chemotherapy and EGFR-TKI. 5. ECOG 0-2, estimated survival time more than 3 months. 6. With no severe bleeding tendency, no acute infection, no obvious liver, kidney or heart dysfunction. 7. Women of reproductive age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, with negative results. 8. Patients volunteer to participate in the study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Non-small cell lung cancer patients with hemoptysis (>20ml/day). 2. Patients with brain metastasis with symptoms or symptoms control time less than 2 months. 3. Patients with any physical signs or history of bleeding. 4. Imaging findings show that tumors have invaded important perivascular areas or that during subsequent treatment, tumors are highly likely to invade important blood vessels and cause fatal hemorrhage. 5. Arteriovenous thrombosis occurred within 6 months, such as cerebrovascular accident, deep venous thrombosis and pulmonary embolism. 6. Severe uncontrollable cardiovascular and cerebrovascular diseases and other important organ diseases, such as uncontrollable hypertension, progressive stroke, diabetes, liver and kidney failure, etc. 7. Drug addiction, chronic alcoholism, and HIV infection. 8. Researchers consider inappropriate to participate in this clinical study.

Design outcomes

Primary

Measure	Time frame
ORR within 3 months;	—

Secondary

Measure	Time frame
PFS;OS;DCR;	—

Countries

China

Contacts

Public ContactWei Suju

Oncology Department, The Fourth Hospital of Hebei Medical University

weisuju@126.com+86 13933856918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026